This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Program award provides $294,995 to Defined Bioscience Inc. to develop low-cost, plant-based protein isolates as a serum replacement for cell culture media used in cultivated meat production. The project aims to identify high-performing plant-derived protein fractions that can replace expensive recombinant albumin, a key component in current cell culture formulations. This work seeks to enable...
This $250,000 National Science Foundation Technology, Innovation, and Partnerships Project Grant supports the development of artificial substrates for growing human stem cells suitable for clinical applications at Oakland University from March 2023 to February 2025. The goal is to accelerate the potential benefits of using human pluripotent stem cells and their derivatives for treating and curing diseases by producing a synthetic substrate that supports growth of human pluripotent stem cells...
This $568,264 Project Grant award (R41HL178144) from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is supporting SAFI Biotherapeutics Inc.'s efforts to develop a scalable, cost-efficient manufacturing process for producing human red blood cells (RBCs) derived from induced pluripotent stem cells (iPSCs). The goal is to create a renewable source of designer RBCs with specific antigen profiles that can be used as reagents to...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $275,396 to Link Biosystems Inc., a self-certified small disadvantaged business, to develop bioreactor technologies for efficient differentiation, scale-up, and maturation of induced pluripotent stem cell (iPSC)-derived cardiomyocytes. The research aims to address challenges in producing clinically relevant quantities of...
This National Science Foundation Project Grant of $100,000 supports research into polyelectrolyte multilayered surfaces for use in human mesenchymal stem/stromal cell manufacturing. The goal is to develop a scalable and controllable polymeric coating composed of natural polymers to improve the cell expansion process used in producing therapeutic human mesenchymal stromal cells. The coating is constructed via layer-by-layer assembly of collagen and heparin and has been shown to increase cell...
This $500,000 Project Grant from the National Science Foundation Division of Molecular and Cellular Biosciences, under the Biological Sciences federal grant program (CFDA 47.074), will support research to develop an end-to-end continuous manufacturing process for cell therapies using robotics and microfluidic technologies. The Georgia Tech Research Corporation will receive funding to create a more integrated workflow based on microfluidic device-enabled genetic engineering, cell expansion, and...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to 37Degrees, Inc. aims to develop a portable and modular system for long-term live cell and tissue culture imaging. The project objectives are to: 1) Enable a personal cellular video microscopy solution to democratize scientists' ability to visualize dynamic biological phenomena over extended time periods, and 2) Overcome technical limitations in maintaining cell...
This STTR project grant awarded by the National Institute of General Medical Sciences (NIGMS), under CFDA 93.859 Biomedical Research and Research Training program, aims to advance the commercialization of an innovative automated cell culturing system. The $295,038 award to Altvivo, Inc. will enable the development of capabilities that overcome limitations of conventional cell culturing technologies. Key objectives include: 1) achieving complex tissue patterns by inducing different cell...
The National Cancer Institute has awarded a $275,627 Project Grant to Link Biosystems Inc., a self-certified small disadvantaged business and for-profit organization, to develop the ONXPANSION bioreactor workflow. This workflow aims to enable efficient expansion of patient-derived induced pluripotent stem cells into clinically relevant cell doses to support autologous cell therapy applications. The grant supports efforts to de-risk the utility of Link Biosystems' bioreactor technology for...
The Stanford University received a three-year $2.83 million Project Grant from the Department of Health and Human Services National Institutes of Health Office of the Director under the Trans-NIH Research Support program (CFDA 93.310). The grant will support development of novel methods to dramatically reduce the cost of stem cell maintenance and increase the scale of organoid production for organ biofabrication applications. Specifically, the university will engineer growth factor-free human...
HIDEF B8: COMMERCIALIZATION AND SCALED PRODUCTION OF DEFINED, ROBUST, AND COST-EFFECTIVE MEDIA FOR IPSCS - RESEARCH & RELATED OTHER PROJECT INFORMATION DEFINED BIOSCIENCE, INC. 7. PROJECT SUMMARY INCONSISTENCY OF GROWTH MEDIA FOR CELL CULTURE IS A SIGNIFICANT PROBLEM IN BOTH INDUSTRY AND ACADEMIA THAT HAS PLAGUED LABORATORIES FOR DECADES. IN BIOPHARMA, CELL-BASED AND CELL-DERIVED THERAPIES ARE GROWING AT A TREMENDOUS RATE AND REQUIRE WELL-DEFINED, ANIMAL-FREE COMPONENTS TO MEET FDA AND CGMP REGULATIONS. IT IS THEREFORE NOT SURPRISING THAT THERE IS AN INCREASED NEED FOR AND ADOPTION OF SERUM-FREE MEDIA FOR CELL CULTURE GROWTH THAT IS ATTRIBUTED TO ITS SUPERIOR BATCH-TO-BATCH CONSISTENCY AND REDUCED RISK OF UNWANTED ANIMAL/XENOBIOTIC CONTAMINANTS. THIS IS PARTICULARLY CRITICAL TO HUMAN INDUCED PLURIPOTENT STEM CELLS (HIPSCS), A RAPIDLY EVOLVING TECHNOLOGY WITH WIDE RESEARCH AND CLINICAL APPLICATION. THESE CELLS PRESENT NUMEROUS ADVANTAGES COMPARED TO PREVIOUS TECHNOLOGIES, INCLUDING HUMAN ORIGIN, THE ABILITY TO FORM MULTI-CLASS CELL SYSTEMS AND TISSUES, RELATIVE EASE OF PRODUCTION AND MODIFICATION, AND FUNCTIONAL RELEVANCE. ROBUST AND WELL- CHARACTERIZED PROTOCOLS ARE OF UTMOST IMPORTANCE WHEN CULTURING HIPSCS FOR DOWNSTREAM APPLICATIONS. HIGH PLURIPOTENCY, GENETIC STABILITY, LARGE-SCALE PRODUCTION AND MAINTAINED FUNCTION ALL MUST BE KEPT IN MIND FOR HIPSCS. YET DESPITE THE ARRAY OF DEFINED MEDIA NOW AVAILABLE FOR IPSCS, MANY OF THESE MEDIA FAIL TO SATISFY THE FULL NEEDS OF HIPSC RESEARCH, INCLUDING ROBUSTNESS OVER MULTIPLE PASSAGES AND EXPERIMENTAL NEEDS, LOW COST, EASE OF PRODUCTION, WEEKEND-FREE MEDIA CHANGES AND FULLY DEFINED COMPONENTS. SUCH TRAITS ARE CRITICAL FOR ROBUST, CONSISTENT AND AFFORDABLE RESEARCH IN THE HIPSC SPACE. JUST THIS YEAR, OUR DEFINED BIOSCIENCE TEAM EMPIRICALLY TESTED COMMON DEFINED MEDIA COMPONENTS OVER A LARGE ARRAY OF CONCENTRATIONS AND COMBINATIONS, ISOLATING A WELL-DEFINED RECIPE WITH HIGH ROBUSTNESS, EFFICACY OVER >100 CELL PASSAGES, AND MAINTAINED SUCCESS IN A WEEKEND-FREE PASSAGING SCHEDULE. THIS MEDIA, TERMED B8 BY THE LAB OF SCIENTIFIC ADVISORY BOARD MEMBER PAUL BURRIDGE, MET OR EXCEEDED THE EXPECTATIONS FOR A PHASE I SBIR DEVELOPMENT PROPOSAL. HERE WE WILL EXTEND THIS WORK TO PREPARE HIDEF B8, A FORMULATION OF B8 FINALIZED TO OPTIMAL COMPONENT CONCENTRATIONS AND REDUCED COST. THIS OPTIMIZED FORMULATION WILL BE TESTED ACROSS ACADEMIC AND INDUSTRIAL LABS IN THE UNITED STATES TO CONFIRM ROBUSTNESS AND EFFICACY IN STREAMLINED AND APPLIED HIPSC CULTURE AND METHODOLOGIES. WE INTEND TO MAKE HIDEF B8 AN AFFORDABLE, DEFINED MEDIA FOR ROBUST HIPSC CULTURE ACROSS HIGH PASSAGE NUMBERS AND IN A WEEKEND-FREE CONTEXT, SIGNIFICANTLY REDUCING THE COST AND COMPLEXITY OF HIPSC TECHNOLOGIES ACROSS THE FIELD. THIS WILL ENABLE STABLE CELL CULTURE AND A WELL-CHARACTERIZED STARTING POINT FOR SUBSEQUENT DIFFERENTIATION AND APPLIED HIPSC TECHNOLOGY EFFORTS, WHILE SIMULTANEOUSLY LOWERING THE BARRIER OF ENTRY FOR HIPSC DEVELOPMENT IN THE FIELD.